Potential Pharma Tariffs Can Have Only Minimal Impact

Chennai: It is likely that potential tariffs on pharmaceutical exports to the United States can only have a minimal effect, since additional costs can be transferred to end consumers by limited absorption by Indian companies.

Although drugs are exempt from mutual tariffs, there is a possibility of sectoral tariffs due to ongoing changes in tariff policies and negotiations between several countries and the US government.

The US General Market is very important for Indian drugs and contributes to approximately 35% of its total income, about $ 10.7 billion. Due to its low -cost, high -volume nature, the United States greatly rely on Indian generics and makes it difficult to replace them with higher cost -cost local production. This protects Indian drugs from future US tariffs because they help reduce the US health costs about $ 15,000 per person.

If a 25 percent tariff is applied, most pharmaceutical companies can shift most of the cost to consumers depending on product competition. They can also reduce their effects by negotiating with US importers, exploring alternative markets, investing in US production or using competitiveness to absorb costs, finding India ratings and research.

However, tariffs exceeding 25 percent can erode competitive advantages and have made it difficult to transfer cost to consumers for low -cost generic, causing market outlets and drug problems in the USA.

However, a decrease in large drug prices may require the supply of the value chain from Indian players, and is ready to achieve this opportunity due to Indian generic, numerous abbreviated new pharmaceutical applications (moment) and US Food and Pharmaceutical Administration (USFDA) approvals.

Indian pharmaceutical companies focus on developed markets such as Europe and Japan from the intensive competitive US general market and other semi -developed markets such as Africa, Latin America and Southeast Asia. Change is directed by growth potential and developing health services and aims to reduce the impact of pricing pressure, increasing regulatory examination and potential trade barriers.